Foundations Investment Advisors LLC Has $417,000 Position in Quest Diagnostics Incorporated $DGX

Foundations Investment Advisors LLC lifted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 59.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,322 shares of the medical research company’s stock after buying an additional 867 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Quest Diagnostics were worth $417,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of DGX. Brighton Jones LLC acquired a new stake in Quest Diagnostics during the fourth quarter worth approximately $323,000. Kestra Private Wealth Services LLC increased its stake in shares of Quest Diagnostics by 50.1% during the first quarter. Kestra Private Wealth Services LLC now owns 2,065 shares of the medical research company’s stock worth $349,000 after purchasing an additional 689 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in shares of Quest Diagnostics by 4.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 8,617 shares of the medical research company’s stock worth $1,458,000 after purchasing an additional 376 shares during the period. Choreo LLC lifted its holdings in Quest Diagnostics by 4.5% during the 1st quarter. Choreo LLC now owns 1,662 shares of the medical research company’s stock worth $281,000 after purchasing an additional 72 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in Quest Diagnostics in the 1st quarter valued at $1,228,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Transactions at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 28,288 shares of the stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total value of $5,293,250.56. Following the completion of the transaction, the senior vice president owned 38,117 shares of the company’s stock, valued at $7,132,453.04. This represents a 42.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gary M. Pfeiffer sold 1,482 shares of the business’s stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $182.40, for a total transaction of $270,316.80. Following the sale, the director directly owned 29,431 shares in the company, valued at approximately $5,368,214.40. The trade was a 4.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,172 shares of company stock valued at $5,639,001 in the last three months. Company insiders own 8.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DGX. UBS Group lifted their target price on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a report on Friday, October 17th. Weiss Ratings reiterated a “buy (b)” rating on shares of Quest Diagnostics in a research note on Wednesday, October 8th. Mizuho increased their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Piper Sandler boosted their price target on Quest Diagnostics from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $196.31.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $186.10 on Thursday. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The company has a market cap of $20.70 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 2.31 and a beta of 0.58. The company has a 50 day moving average of $183.21 and a 200-day moving average of $178.40. Quest Diagnostics Incorporated has a 1-year low of $148.70 and a 1-year high of $197.55.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, beating the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the previous year, the business earned $2.30 earnings per share. The company’s revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, equities research analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 13th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Tuesday, January 13th. This represents a $3.20 annualized dividend and a yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.